The World Health Organization (WHO) is seeking experts to serve as members of the Strategic and Technical Advisory Group for Neglected Tropical Diseases. This “Call for Experts” notice provides information about the advisory group in question, the expert profiles being sought, the process to express interest, and the process of selection.
Background
The Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTD) is the main advisory body to World Health Organization in this field.
NTDs are a diverse set of bacterial, viral, parasitic, fungal and noncommunicable diseases and disease groups that disproportionately affect populations living in poverty, predominantly in tropical and subtropical areas. Twenty diseases and disease groups are currently included in the NTD portfolio, and currently more than one billion people are affected.
STAG-NTD advises and makes policy and strategic recommendations to WHO, based on independent reviews of progress made and challenges faced by programmes and partners, with the aim of facilitating the achievement of the targets and milestones set by the NTD road map 2021–2030.
Functions of the Strategic and Technical Advisory Group for Neglected Tropical Diseases
In its capacity as an advisory body to WHO, the STAG-NTD shall have the following functions:
- To provide to WHO independent evaluation of the adequacy of progress towards the targets and milestones of the NTD road map 2021–2030;
- To review, and make recommendations to WHO for overcoming, challenges to achieving the targets and milestones of the NTD road map 2021–2030;
- To review, and make recommendations to WHO on increasing, the adoption of the three fundamental shifts in approach to tackling NTDs specified in the NTD road map 2021–2030
Operations of the Strategic and Technical Advisory Group for Neglected Tropical Diseases
The STAG-NTD will normally meet in person once a year at WHO Headquarters in Geneva, Switzerland, usually for 2-3 days. Depending on the issues at stake, additional interim meetings may be organized in the course of the year. The working language of the STAG-NTD will be English.
Who can express interest?
The STAG-NTD will be multidisciplinary, with members having a range of technical knowledge, skills and experience relevant to NTDs and of the challenges faced by programmes and partners within the context of health systems in NTD-endemic countries. Up to approximately 20 members may be selected.
WHO welcomes expressions of interest from individuals with knowledge, skills and experience in:
To register your interest in being considered for the [name of the advisory group], please submit the following documents by 24:00h (midnight) Geneva time on 16 July 2022 to aimel@who.int using the subject line “Expression of interest for the STAG-NTD”.
After submission, your expression of interest will be reviewed by WHO. Due to an expected high volume of interest, only selected individuals will be informed.
Members of WHO advisory groups (AGs) must be free of any real, potential or apparent conflicts of interest. To this end, applicants are required to complete the WHO Declaration of Interests for WHO Experts, and the selection as a member of an AG is, amongst other things, dependent on WHO determining that there is no conflict of interest or that any identified conflicts could be appropriately managed (in addition to WHO’s evaluation of an applicant’s experience, expertise and motivation and other criteria).
All AG members will serve in their individual expert capacity and shall not represent any governments, any commercial industries or entities, any research, academic or civil society organizations, or any other bodies, entities, institutions or organizations. They are expected to fully comply with the Code of Conduct for WHO Experts (https://www.who.int/about/ethics/declarations-of-interest). AG members will be expected to sign and return a completed confidentiality undertaking prior to the beginning of the first meeting.
At any point during the selection process, telephone interviews may be scheduled between an applicant and the WHO Secretariat to enable WHO to ask questions relating to the applicant’s experience and expertise and/or to assess whether the applicant meets the criteria for membership in the relevant AG.
The selection of members of the AG will be made by WHO in its sole discretion, taking into account the following (non-exclusive) criteria: relevant technical expertise; experience in international and country policy work; communication skills; and ability to work constructively with people from different cultural backgrounds and orientations .The selection of AG members will also take account of the need for diverse perspectives from different regions, especially from low and middle-income countries, and for gender balance.
If selected by WHO, proposed members will be sent an invitation letter and a Memorandum of Agreement. Appointment as a member of an AG will be subject to the proposed member returning to WHO the countersigned copy of these two documents.
WHO reserves the right to accept or reject any expression of interest, to annul the open call process and reject all expressions of interest at any time without incurring any liability to the affected applicant or applicants and without any obligation to inform the affected applicant or applicants of the grounds for WHO's action. WHO may also decide, at any time, not to proceed with the establishment of the AG, disband an existing AG or modify the work of the AG.
WHO shall not in any way be obliged to reveal, or discuss with any applicant, how an expression of interest was assessed, or to provide any other information relating to the evaluation/selection process or to state the reasons for not choosing a member.
WHO may publish the names and a short biography of the selected individuals on the WHO internet.
AG members will not be remunerated for their services in relation to the AG or otherwise. Travel and accommodation expenses of AG members to participate in AG meetings will be covered by WHO in accordance with its applicable policies, rules and procedures.
The appointment will be limited in time as indicated in the letter of appointment.
If you have any questions about this “Call for experts”, please write to aimel@who.int well before the applicable deadline.
The Global Health Network, EDCTP, and Women’s College Hospital at the University of Toronto have extended their partnership to provide continued access to the SPIRIT Electronic Protocol Tool and Resource (SEPTRE) platform. Through this collaboration, a limited number of free three-year licenses remain available for researchers in low- and middle-income countries (LMICs) who may not otherwise afford access.
SEPTRE is an online tool that helps researchers design, manage, and register high-quality clinical trial protocols in line with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines, which were updated in 2025. The update introduced new sections on open science, harms assessment, intervention descriptions, and patient and public involvement.
Applications can be submitted through the EDCTP Knowledge Hub SEPTRE enquiry form. Applicants should be located in a low- or middle-income country (preference is given to researchers based in Africa and who are members of the EDCTP Knowledge Hub). We encourage applicants via the form to state their goals and objectives to apply for a SEPTRE license and the research they want to undertake. Successful applicants agree that they will submit a yearly report on how they have made use of the license.
Learn more about the EDCTP Knowledge Hub.
Read moreThe EDCTP Association deeply mourns the loss of Professor Jean Louis Abdourahim Ndiaye, joining the global health community in honouring an outstanding researcher whose impact will continue to be felt across the global health research field.
Professor Ndiaye was awarded a Senior Fellowship in 2011 under the EDCTP1 programme to conduct research on seasonal malaria chemoprophylaxis (SMC). He led transformative malaria prevention research, including innovative seasonal intermittent preventive treatment in children (IPTc), and continued to develop his research on preventing and protecting children from malaria. At the University of Thiès, Senegal, he built a research team and went on to head the OPT-SMC project, funded under the EDCTP2 programme, which focused on strengthening the capacity of national malaria control programmes in conducting implementation research to improve SMC delivery and impact. This project supported 13 countries across West and Central Africa (Benin, Burkina Faso, Cameroon, Chad, The Gambia, Ghana, Guinea, Guinea-Bissau, Mali, Mauritania, Niger, Nigeria, Senegal, and Togo), bringing together national malaria programme representatives to share expertise and tailor interventions to local contexts.
Professor Ndiaye was not only a leading scientist but also a kind and humble man, deeply committed to reducing the burden of malaria in Africa and developing the next generation of African researchers. His contributions have made a significant impact on malaria control and implementation research. His passing is a considerable loss to the global scientific community, particularly in Africa. He will be deeply missed. We extend our condolences to his family, friends, and colleagues.
Read moreIn his EDCTP-GSK Senior Fellowship, Professor George Boateng Kyei of the Noguchi Memorial Institute for Medical Research, University of Ghana, has not only advanced the search for an HIV cure but also strengthened research capacity across Ghana and the broader African region.
HIV remains a pressing public health issue in Africa, with persistent challenges hindering the quest for a cure. This fellowship project focused on one such challenge: the virus’s ability to remain dormant within resting CD4+ T cells, even among individuals receiving antiretroviral therapy (ART). By exploring the innovative “shock and kill” approach, the research aimed to reactivate latent HIV and target infected cells for destruction. A notable scientific achievement was the identification and confirmation of three novel epigenetic compounds capable of reactivating latent HIV from virologically suppressed individuals. These findings pave the way for future studies in animal models, with the potential to transition into clinical trials aiming at finding a cure for HIV.
The establishment of a drug screening platform at the University of Ghana stands out as a long-term asset for HIV drug discovery and cure research. Additionally, the project introduced regular viral load monitoring for a substantial cohort of patients—an essential practice previously not standard in Ghana. The data generated from this monitoring has been instrumental in shaping national HIV treatment policies and improving patient care.
Furthermore, the project developed a biobank and a well-characterised cohort of HIV-infected adults, providing invaluable resources for ongoing and future HIV cure research. Insights gathered from patients regarding their perceptions of HIV cure research will inform the design and conduct of subsequent studies in Ghana and across Africa.
The impact of the fellowship extends beyond laboratory accomplishments; it has significantly influenced research training and career development. The fellowship helped nurture the growth of junior scientists, many of whom have evolved into independent research leaders, securing competitive grants and fellowships, such as the IAS Research-for-Cure Academy and NIH R21. They have presented their findings at prestigious international conferences, including the African Virology Congress and the American Society of Tropical Medicine and Hygiene (ASTMH).
Post-doctoral fellows have notably received fellowships from esteemed international programmes, such as the Science by Women Fellowship and the NIH CFAR Africure award, showcasing their growing prominence in the research community.
Professor Kyei’s mentorship has not gone unnoticed; in April 2024, he received special recognition from the University of Ghana’s Centre for Gender Studies and Advocacy (CEGENSA) for his outstanding mentorship of female academics—an honour highlighted by nominations from his own mentees. The project also celebrated the achievements of its team members, with one post-doc winning Best Senior Research Fellow at the 2024 NMIMR Awards and research assistants earning accolades at the 2024 African Virologist Conference.
Professor Kyei’s research has led to significant international visibility, with his team members winning travel awards to attend prestigious conferences, including the Keystone Symposium and the African Virology Congress. These opportunities have allowed them to present their findings and collaborate with global experts in the field.
The EDCTP-GSK Senior Fellowship grant has facilitated the groundwork for additional projects, including a newly awarded Fogarty grant aimed at enhancing HIV basic science and cure research training at the University of Ghana. This grant will train 17 researchers over the next 5 years, further strengthening the research landscape in Ghana.
As the team looks to the future, plans are in place to expand research into HIV reservoir characteristics among virologically suppressed patients across Ghana. This extension not only continues the momentum generated by the EDCTP grant, but also reinforces Ghana’s position as a leader in HIV cure research in Africa and contributes to the global effort to eradicate HIV.